Pattern analysis and variations in the utilization of antihypertensive drugs in Taiwan: A six-year study

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 3, 2013, Pages 410-419

  Huang, L Y ^a,b   Shau, W Y ^a   Chen, H C ^b   Su, S ^b   Yang, M C ^b   Yeh, H L ^c,d   Lai, M S ^b,e  

^a Center for Drug Evaluation   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II receptor blockers; Antihypertensive drugs; Calcium channel blockers; Total defined daily dose

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ARTICLE; DATA BASE; DEFINED DAILY DOSE; DEFINED DAILY DOSE PER 1000 INHABITANTS PER DAY; DRUG DOSE; DRUG UTILIZATION; HEALTH INSURANCE; HUMAN; PRESCRIPTION; TAIWAN; WORLD HEALTH ORGANIZATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DATABASES, FACTUAL; HUMANS; HYPERTENSION; NATIONAL HEALTH PROGRAMS; PRACTICE GUIDELINES AS TOPIC; SODIUM CHLORIDE SYMPORTER INHIBITORS; TAIWAN;

EID: 84878615224     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. KLUNGEL OH, DE BOER A, PAES AH, SEIDELL JC, BAKKER A. Sex differences in the pharmacological treatment of hypertension: A review of population-based studies. J Hypertens 1997; 15: 591-600.
2. REEVES RA. Does this patient have hypertension? How to measure blood pressure. JAMA 1995; 273: 1211-1218.
3. BENNETT S. Blood pressure measurement error: Its effect on cross-sectional and trend analyses. J Clin Epidemiol 1994; 47: 293-301.
4. GUIBERT R, FRANCO ED. Choosing a definition of hypertension: Impact on epidemiological estimates. J Hypertens 1996; 14: 1275-1280.
5. CHOU CC, LEE MS, KE CH, CHUNG MH. Prescription patterns of hypertension-National Health Insurance in Taiwan. J Chin Med Assoc 2004; 67: 123-130.
6. CHIANG TL: Taiwan's 1995 health care reform. Health Policy 1997; 39: 225-239.
7. NATIONAL HEALTH INSURANCE RESEARCH DATABASE, AVAILABLE AT: http://w3.Nhri.Org.Tw/nhird//date-01.Html. [Date accessed: October 03, 2012].
8. WHO COLLABORATING CENTER FOR DRUG STATISTICS METHODOLOGY. Guidelines for ATC classification and DDD assignment 2012. Oslo, 2011. Available at: Http://www.Whocc.No/filearchive/publications/2012-guidelines-with-front-pa.Pdf. [Date accessed: September 27, 2012].
9. WHO COLLABORATING CENTER FOR DRUG STATISTICS METHODOLOGy. ATC Index with DDDs 2003. WHO: Oslo, 2003.
10. DEFINITION AND GENERAL CONSIDERATIONS OF THE DEFINED DAILY DOSE (DDD). Available at: http://www.Whocc.No/ddd/definition-and-general-considera/. [Date accessed: October 03, 2012].
11. NATIONAL STATISTICS, REPUBLIC OF CHINA (TAIWAN). Available at: http://eng.Stat.Gov.Tw/mp.Asp?Mp=5. [Date accessed: October 03, 2012].
12. AUSTRALIAN CENTRE FOR ASTHMA MONITORING 2007. Patterns of asthma medication use in Australia. Aihw cat. No. Acm 11. Canberra: Australian Institute of Health and Welfare. Available at: http://www.Asthmamonitoring.Org/ pdf/07-pbs-report.Pdf. [Date accessed: October 03, 2012].
13. BUREAU OF NATIONAL HEALTH INSURANCE. National Health Insurance Annual statistical report. Taipei: Bureau of National Health Insurance; 2001.
14. CAPELLÀ D. Descriptive tools and analysis. WHO Reg Publ Eur Ser 1993; 45: 55-78.
15. NATSCH S, HEKSTER YA, DE JONG R, HEERDINK ER, HERINGS RM, VAN DER MEER JW. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis 1998; 17: 20-24.
16. OECD. StatExtracts. Available at: http://stats.oecd.org/index.aspx? DataSet-Code=HEALTH-STAT [Date accessed: October 03, 2012].
17. COHEN R, FONTBONNE A, WEITZMAN S, ESCHWEGE E. Estimation of the prevalence of diabetes mellitus in israel based on hypoglycemic drug supply and consumption. Diabete Metab 1990; 16: 59-63.
18. FELDMAN HI, STROM BL. Utilisation of drugs for diabetes mellitus. Drug Safety 1991; 6: 220-229.
19. ÅLHAMMAR J BU, BOMAN K, DAHLÉN M. Metabolic control in diabetic subjects in three swedish areas with high, medium, and low sales of anti diabetic drugs. Diabetes Care 1991; 14: 12-19.
20. BIRKETT DJ, MITCHELL AS, GODECK A, GRIGSON T, CULLY R, LEE C. Profiles of antibacterial drug use in australia and trends from 1987 to 1989. A report from the drug utilization subcommittee of the pharmaceutical benefits advisory committee. Med J Aust 1991; 155: 410-415.
21. CAPELLÀ D, PORTA M, LAPORTE JR. Utilization of antihypertensive drugs in certain European countries. Eur J Clin Pharmacol 1983; 25: 431-435.
22. OREBERG M, JONSSON GG, WEST K, EBERHARD-GRAHN M, RÅSTAM L, MELANDER A. Large intercommunity difference in cardiovascular drug consumption: relation to mortality, risk factors and socioeconomic differences. Eur J Clin Pharmacol 1992; 43: 449-454.
23. MERLO J, RANSTAM J, RÅSTAM L, WESSLING A, MELANDER A. Age standardisation of drug utilisation: Comparisons of different methods using cardiovascular drug data from sweden and spain. Eur J Clin Pharmacol 1994; 46: 393-398.
24. MERLO J, LINDBERG G, LINDBLAD U, LINDGREN A, RÅSTAM L, MELANDER A. Utilization of cardiovascular drugs (blood pressure lowering drugs, lipid lowering drugs and nitrates) and mortality from ischaemic heart disease and stroke. An ecological analysis based on Sweden's municipalities. Eur J Clin Pharmacol 1999; 55: 69-76.
25. BUSTO U, LANCTÔT KL, ISAAC P, ADRIAN M. Benzodiazepine use and abuse in Canada. CMAJ 1989; 141: 917-921.
26. RUIZ I, OFFERMANNS J, FUENTES P, CASTILLO M. Utilization of benzodiazepines in Chile during 1982-1986. Eur J Clin Pharmacol 1989; 37: 139-143.
27. KEARNEY PM, WHELTON M, REYNOLDS K, MUNTNER P, WHELTON PK, HE J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217-223.
28. CHOI KM, PARK HS, HAN JH, LEE JS, LEE J, RYU OH, LEE KW, CHO KH, YOON D, BAIK SH, CHOI DS, KIM SM. Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006; 24: 1515-1521.
29. CHIEN KL, HSU HC, SUNG FC, SU TC, CHEN MF, LEE YT. Incidence of hypertension and risk of cardiovascular events among ethnic Chinese: report from a community-based cohort study in Taiwan. J Hypertens 2007; 25: 1355-1361.
30. WU CJ, LIN KC, CHEN ST, LAI WT, LIU CP, CHIANG SS, HUANG YY, FERRARI P. Assessment of reasons for not intensifying antihypertensive treatment in the Taiwanese population. J Formos Med Assoc 2011; 110: 768-774.
31. CHIANG CE, CHEN CH. Hypertension in the Asia-Pacific region. J Hum Hypertens 2008; 22: 441-443.
32. KLONER RA, VETROVEC GW, MATERSON BJ, LEVENSTEIN M. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Am J Cardiol 1998; 81: 163-169.
33. ABERNETHY DR. An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol 1994; 73: 10A-77A.
34. DIMENAS E, WALLANDER MA, SVARDSUDD K, WIKLUND I. Aspects of the quality of life on treatment with felodipine. Eur J Clin Pharmacol 1991; 40: 141-147.
35. ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
36. LIOU YS, MA T, TIEN L, CHIEN C, CHOU P, JONG GP. Long-term effects of antihypertensive drugs on the risk of new-onset diabetes in elderly Taiwanese hypertensives. Int Heart J 2008; 49: 205-211.
37. CHIANG CE, WANG TD, LI YH, LIN TH, CHIEN KL, YEH HI, SHYU KG, TSAI WC, CHAO TH, HWANG JJ, CHIANG FT, CHEN JH; HYPERTENSION COMMITTEE OF THE TAIWAN SOCIETY OF CARDIOLOGY. Hypertension Committee of the Taiwan Society of Cardiology. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc 2010; 109: 740-773.
38. TSUJI RL, SILVA GV, ORTEGA KC, BERWANGER O, MION JÚNIOR D. An economic evaluation of antihypertensive therapies based on clinical trials. Clinics (Sao Paulo) 2012; 67: 41-48.
39. DOYLE J, OMVIK P, ARIKIAN S, CASCIANO J, CASCIANO R, GONZALEZ MA, AROCHO R. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. Manag Care Interface 2001; 14: 82-87.
40. NORDMANN AJ, KRAHN M, LOGAN AG, NAGLIE G, DETSKY AS. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy. Pharmacoeconomics 2003; 21: 573-585.
41. WILLIAMS B, POULTER N, BROWN M, DAVIS M, MCINNES G, POTTER J, SEVER PS, THOM SM; BHS GUIDELINES WORKING PARTY, FOR THE BRITISH HYPERTENSION SOCIETY. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br Med J 2004; 328: 634-640.
42. CHOBANIAN AV, BAKRIS GL, BLACK HR, CUSHMAN WC, GREEN LA, IZZO JL JR, JONES DW, MATERSON BJ, OPARIL S, WRIGHT JT JR, ROCCELLA EJ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE JOINT NATIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE; NATIONAL HIGH BLOOD PRESSURE EDUCATION. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
43. KIDNEY DISEASE OUTCOMES QUALITY INITIATIVE (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(5 Suppl 1): S1-290.
44. EUROPEAN SOCIETY OF HYPERTENSION-EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES COMMITTEE. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
45. CONLIN PR, GERTH WC, FOX J, ROEHM JB, BOCCUZZI SJ. Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001; 23: 1999-2010.
46. ROSS S, MACLEOD MJ. Antihypertensive drug prescribing in Grampian. Br J Clin Pharmacol 2005; 60: 300-305.
47. MATCHAR DB, MCCRORY DC, ORLANDO LA, PATEL MR, PATEL UD, PATWARDHAN MB, POWERS B, SAMSA GP, GRAY RN. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Nov.